Vilazodone

Drug Profile

Vilazodone

Alternative Names: EMD-68843; SB-659746A; Viibryd; Vilazodone hydrochloride

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer Allergan; moksha8 Pharmaceuticals
  • Class Amides; Antidepressants; Benzofurans; Indoles; Nitriles; Piperazines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase III Generalised anxiety disorder
  • Phase II Social phobia
  • Phase I Sexual function disorders

Most Recent Events

  • 01 Oct 2016 Forest Laboratories completes a phase III trial for Major depressive disorder (in adolescents) in USA (NCT01878292)
  • 01 Apr 2015 Forest initiates enrolment in a phase III trial for Major depressive disorder (In children, In adolescents, aged 7-17 years) in USA (NCT02436239)
  • 16 Mar 2015 The US FDA approves sNDA for a lower therapeutic dose of vilazodone for Major depressive disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top